Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095.
In AIDS Clinical Trials Group A5095, 9% of participants who experienced an adverse event related to efavirenz substituted nevirapine. Most adverse events resolved; 15 participants ultimately discontinued nevirapine therapy. Grade 3/4 hepatotoxicity was observed in 14% of individuals who substituted nevirapine, compared with 6% who continued efavirenz therapy. Substitution of nevirapine because of efavirenz toxicity was generally safe and efficacious. Clinical trials registration. NCT00013520 .
Schouten
Jeffrey T
JT
University of Washington, Seattle, USA. schouten@u.washington.edu
Krambrink
Amy
A
Ribaudo
Heather J
HJ
Kmack
Anne
A
Webb
Nancy
N
Shikuma
Cecilia
C
Kuritzkes
Daniel R
DR
Gulick
Roy M
RM
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D000328:Adult; D000480:Alkynes; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D048588:Benzoxazines / Q000009:adverse effects* / Q000627:therapeutic use*; D003521:Cyclopropanes; D005260:Female; D006801:Humans; D008099:Liver / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D019829:Nevirapine / Q000009:adverse effects* / Q000627:therapeutic use*; D028761:Withholding Treatment
D000480:Alkynes; D000998:Antiviral Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D019829:Nevirapine; C098320:efavirenz